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ABSTRAK
Tujuan: untuk mengevaluasi efektivitas biaya (cost-effectiveness) perluasan layanan (scaling-up) VCT 
berbasis masyarakat di Jawa Barat. Metode: Asian epidemic modelling (AEM) dan resource need model 
(RNM) digunakan untuk menghitung biaya-biaya tambahan untuk setiap infeksi HIV yang dihindari dan setiap 
disability-adjusted life years (DALYs) yang diselamatkan. Data demografi, perilaku dan biaya hasil pantauan 
lokal yang berhubungan dengan epidemic digunakan sebagai input pada model. Hasil: memperluas cakupan 
layanan VCT berbasis masyarakat  di Jawa Barat akan mengurangi prevalensi di keseluruhan populasi sebesar 
36% pada tahun 2030 dan dengan biaya US$ 248 per infeksi HIV yang terhindari dan US$ 9.17 per DALY yang 
diselamatkan. Perkiraan efektivitas biaya yang paling sensitif adalah terhadap dampak VCT pada penggunaan 
kondom dan jumlah populasi klien pekerja seks wanita (WTS), dan dampaknya secara keseluruhan kuat. Total 
biaya untuk scaling-up VCT berbasis masyarakat berkisar antara US$ 1,3 dan 3,8 juta per tahun dan memerlukan 
sejumlah klinik VCT terintegrasi di puskesmas untuk meningkatkan dari 6 klinik di 2010 menjadi 594 klinik di 
tahun 2030. Kesimpulan: scaling up VCT berbasis masyarakat merupakan intervensi efektif dan hemat biaya. 
Namun, untuk memprioritaskan VCT dalam pengendalian HIV/AIDS di Jawa Barat, masalah ketersediaan 
anggaran dan kapasitas organisasi harus diatasi.
Kata kunci: infeksi HIV, konseling & tes suka rela, analisis efektivitas biaya, pengambilan keputusan.
ABSTRACT
Aim: to evaluate the costs-effectiveness of scaling up community-based VCT in West-Java. Methods: the Asian 
epidemic model (AEM) and resource needs model (RNM) were used to calculate incremental costs per HIV infection 
averted and per disability-adjusted life years saved (DALYs). Locally monitored demographic, epidemiological 
behavior and cost data were used as model input. Results: scaling up community-based VCT in West-Java will 
reduce the overall population prevalence by 36% in 2030 and costs US$248 per HIV infection averted and US$9.17 
per DALY saved. Cost-effectiveness estimation were most sensitive to the impact of VCT on condom use and to 
the population size of clients of female sex workers (FSWs), but were overall robust. The total costs for scaling up 
community-based VCT range between US$1.3 and 3.8 million per year and require the number of VCT integrated 
clinics at public community health centers to increase from 73 in 2010 to 594 in 2030. Conclusion: scaling up 
community-based VCT seems both an effective and cost-effective intervention. However, in order to prioritize VCT 
in HIV/AIDS control in West-Java, issues of budget availability and organizational capacity should be addressed.
Key words: HIV infections, voluntary counselling and testing, cost-effectiveness analysis, decision maker.
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INTRODUCTION
In most Asian countries national HIV 
epidemics are stabilizing, but Indonesia’s is 
growing.1 The epidemic is concentrated among 
risk groups, such as injecting drug users (IDUs) 
and female sex workers (FSWs), except in Papua 
province, where it is generalized.2 In 2009, the 
prevalence of people living with HIV/AIDS 
(PLWHA) was estimated at 353,173 (0.3%) and 
long-term projections vary between 500,000-
1,000,000 in 2015. Importantly, these projections 
indicate a shift of the epidemic towards the 
general population.3,4
Indonesia’s national response focuses on a 
wide range of services, mainly for most-at-risk 
populations: e.g. harm reduction programs, 
condom distribution, and voluntary counseling 
and testing (VCT).3 Unfortunately, coverage of 
VCT remains low, approximately 30% among 
most-at-risk populations in 2009.3 As a result, 
HIV patients present themselves at hospitals and 
at a very late stage, reflected in extremely low 
median CD4 cell counts (33/ml among IDUs 
and 84/ml among non-IDUs).5 VCT functions 
as an entry point for care and counselors aim 
to reduce the risk behavior of tested individuals 
by providing information about routes of HIV 
transmission and about prevention methods.6 
Because VCT is able to prevent the spread of 
HIV, it is a key component in Indonesia’s HIV/
AIDS control. Based on WHO guidelines, VCT 
services in Indonesia consist of HIV rapid testing 
combined with pre- and post-test counseling. In 
line with the WHO/UNAIDS goals for universal 
access to VCT in 2010, the National AIDS 
Commission (NAC) proposes in their National 
Strategy 2010-2014 to scale up VCT to 80% 
among most-at-risk groups in 2014.3,7
To date, VCT is mainly delivered at hospitals, 
but several researchers stress the need for a 
community-based approach to promote early 
detection and treatment and to reduce case loads 
at hospitals.8,9 Moreover, Siregar et al.8 showed 
that in Indonesia community health centers 
provide VCT at significantly lower costs than 
hospitals. However, the total costs and health 
effects of scaling up VCT at community level 
are not yet clear. The rise in costs caused by the 
increasing number of people covered might be 
largely offset by a decrease in unit costs of VCT. 
In addition, the cost-effectiveness of VCT is 
largely unknown.
The Indonesian government substantially 
increased economic efforts to combat the HIV 
epidemic: the allocation from the national budget 
rose from US$11 to 73 million between 2006 
and 2009.3 This is encouraging, but it will not 
be enough to implement every intervention for 
every target group at full scale, emphasizing the 
urgent need for setting priorities for HIV/AIDS 
interventions.10 Cost-effectiveness is proposed 
as a leading criterion in setting such priorities, 
but evidence on the cost-effectiveness of HIV/
AIDS interventions is largely unavailable in 
Indonesia.10 In addition, international literature 
is difficult to generalize and focuses mainly on 
Africa.11
Against this background, our study aims to 
evaluate the costs, effects, and cost-effectiveness 
of scaling up community-based VCT in West-
Java in order to support the national strategy 
as well as policy makers in setting priorities 
for HIV/AIDS interventions. Our study is an 
integrated component of a broader project on 
the economic analysis of HIV/AIDS control in 
Bandung, West-Java that also includes cost12 
and cost-effectiveness studies on methadone 
maintenance treatment (MMT).13
METHODS
Study Setting
Our area of analysis is the province of West 
Java, with 40 million inhabitants and a high HIV 
prevalence in most-at-risk populations: 42.8% in 
IDUs, 11.6% in direct FSWs, and 3.3% in indirect 
FSW (direct FSWs are those working in brothels 
and indirect FSWs are those working in bars and 
hotels), and 2.0% in men having sex with men 
(MSM), according to most recent estimates in 
2007. In 2010, West-Java reported a prevalence 
of 2,168 HIV infections and 3,512 AIDS cases,14 
although mathematical models (Asian Epidemic 
Model for West-Java) had projected 35,294 and 
3,856, respectively. At time of research in West-
Java, 167 VCT clinics are integrated in hospitals, 
public and private community health centers, and 
prisons. Between April 2006 and November 2009 
these clinics provided VCT services to 27,807 
people. However, in 2009 overall coverage was 
only 30% among the majority of most-at-risk 
populations and 2% among clients of FSWs 
(Table 1).3,7 Because many stakeholders agreed 
upon a strategy of scaling up community-based 
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VCT services, advocacy and capacity building has 
recently begun to successfully integrate more VCT 
clinics in existing public community health centers 
(i.e. Puskesmas).7 So far, these clinics provide 
VCT services to 30 people per year, but have the 
capacity to test and counsel 300 people per year, 
as estimated by the Ministry of Health (MoH).15
Scaling up Community-based VCT versus 
Current Practice 
We compare the costs and effects of scaling 
up community-based VCT versus a base case 
of current practice, over the years 2010-2030, 
from a government perspective. We calculated 
incremental cost-effectiveness ratios (ICER) per 
HIV infection averted and disability adjusted live 
years (DALYs). The base case and scaling up 
strategy were defined as follows:
Current practice (base case). In this situation, 
VCT services target only most-at-risk populations: 
indirect and direct FSWs, IDUs, higher risk 
MSM, transgenders, clients of FSWs, prisoners, 
and partners of IDUs. We assumed that VCT 
coverage among risk populations in 2009 remains 
stable until 2030 (Table 1) and that 60% of the 
people targeted receive VCT at hospitals, 20% at 
private community health centers, 10% at public 
community health centers, and 10% at prisons, 
reflecting current practice.16 Unit costs of VCT 
per client depend on where the client is tested 
and counseled (i.e. health centers, hospitals, or 
prisons).
Scaling up VCT at the community level. In 
this situation, VCT will be scaled up at public 
community health centers according to the 
National Strategy 2010-2014, as specific targets 
for West-Java province are not available.7,17 
“Community level” is defined as providing 
services at close distance to the living area of the 
target group, in public community health centers 
(i.e. Puskesmas) in both urban and rural areas. 
Coverage among most-at-risk populations will 
increase from approximately 30% in 2009 to 80% 
in 2014 and will remain stable until 2030 (Table 
1). We assumed that hospitals will no longer 
offer VCT services, that the number of people 
tested and counseled at private community health 
centers and prisons remains stable, and that the 
additional people covered receive VCT at public 
community health centers. In this situation, 
85.4% of the targeted people receive VCT at 
public community health centers, 3.2% at private 
community health centers, 11.4% at prisons and 
0% at hospitals. The most-at-risk populations 
targeted, the VCT unit costs, and the capacity of 
public community health centers are similar as 
the defined base case.
Study Model
We projected costs and effects using a 
combined Asian epidemic model (AEM)18,19 and 
Resource needs model (RNM).20 Both models are 
widely published and are the primary and only 
source of data on the HIV/AIDS epidemic for 
the Ministry of Health in Indonesia.4,7 A detailed 
description of the models and the data sources 
used can be found in the online Appendix (www.
niche1.nl/publications).
Because of model limitations we only 
modeled the impact of a reduction of condom use 
in contacts between direct and indirect FSWs and 
their clients, IDUs and FSWs and their spouses 
or regular partners, and between MSM and their 
male partners. In our sensitivity analysis we 
anticipated on the over- or underestimation of the 
effectiveness of VCT, as the impact matrix does 
not capture studies from Indonesia on the impact 
of VCT. However, in the literature we found 
one qualitative study on the impact of VCT on 
40 IDUs in Bali that reported that of those who 
tested positive, 50% reported decreased risky 
drug use and 37.5% decreased risky sex. The 
individuals with negative test results showed the 
same changes.21 In addition, we assumed equal 
impact of VCT over risk groups, as we found no 
evidence for differences in the literature.22 The 
costs of VCT coverage were included for all 
most-at-risk populations.
Estimate of DALYs Saved
AEM output (number of new HIV infections, 
AIDS cases, and deaths of men and women) was 
used to estimate DALYs for both the base case 
and the strategy of scaling up VCT, based on the 
following Global Burden of Disease formulas:23 
DALY = YLL + YLD
Years of lives lost (YLL) due to AIDS related 
death:
YLL r,K,s | | K eC ra
( | )r 
2
[ ] [ | ][ | ] 1|e r L a
( )r| KL|a|

- | - ( +r ) - 1|) + (1- )e a e
r
( )r( |a| rL
 1 K
K=age weighting modulation factor;  C=constant; r=discount 
rate; a=age of death; β=parameter from age weighting 
function;  L=standard expectation of life at age.
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Years lived in disability (YLD) (separated 
for disease stages of HIV-infection and AIDS):
in Bandung, West-Java (Table 2).8 Health care 
costs were estimated on the basis of data on 
service utilization retrieved from clinic records and 
unit costs, including all resources consumed and 
valued using a micro-costing approach. All costs 
were measured in rupiah, and converted to US$ 
using the 2008 exchange rate. Based on a MoH 
workshop with HIV/AIDS experts in West-Java, 
the health care costs for public community health 
centers were adjusted from 28 to 300 people per 
year to reflect normal capacity.15 In all settings 
the VCT service is in line with the standard VCT 
delivery procedure instructed by the MoH: VCT 
includes a separate room for counseling and well-
trained counselors. Differences among clinics in 
capital personnel training and workshop costs are 
explained by differences in training quality and 
number of staff trained. Differences in recurrent 
personnel costs are caused by differences in 
number of admin staff, salary and time spend 
per VCT service. We assumed that only private 
community health centers have outreach teams. 
Additional costs for scaling up services were not 
included as the unit costs include capital costs 
reflecting costs for new buildings and training 
costs for new VCT counselors.
Table 2. Annual costs of delivering VCT service for different clinic settings (US$, 2008 exchange rate)8
Type of cost/clinic setting
Public
community
health center†
Private 
community
health center
Hospital Prison
Capital costs (annualized)
Personnel training, & workshops 207 (4.6§) 4,220 (10.0) 145 (0.5) 4,194 (32.4)
Building/space 181 (4.0) 266 (0.6) 657 (2.3) 1,624 (12.5)
Equipment 297 (6.6) 351 (0.8) 657 (2.3) 30 (0.2)
Subtotal 685 4,837 1,459 5,848 
Capital cost per VCT 2 6 3 10
Recurrent costs
Personnel 615 (13.8) 21,051 (50.0) 21,633 (74.9) 2,116 (16.4)
Supplies 2,297 (51.4) 10,007 (23.8) 2,591 (9.0) 539 (4.2)
Outreach team activities - 6,186 (14.7) - -
Laboratory 874 (19.5) - ¥ 3,255 (11.2) 4,439 (34.3)
Subtotal 3,787 37,244 27,479 7,093
Recurrent cost per VCT 12 48 65 12
Total annual cost 4,472 42,080 28,938 12,941
Clinic capacity (number of VCTs per year) 300 784 421 574
Unit cost per VCT 14.91 53.37 68.74 22.55
† Adapted to 300 patients per year
§ Percentage of total costs 
¥ Not costed separately, but included in the capital and recurrent cost items
YLD r,K,s | | K eC ra
( | )r 
2
[ ] [ | ][ | ] 1|e r L a
( )r| KL|a|

- | - ( + ) - 1|) + (1- )e r a e
r
( )r( |a| rL
 1 K
D |
K=age weighting modulation factor;  C=constant; r=discount 
rate; a=age of onset of disability; β=parameter from age 
weighting function;  L=duration of disability; D=disability 
weight.
For men and women disability weights were 
0.136 for HIV infection (0.123 until 15 years old) 
and 0.505 for AIDS, the average duration in the 
HIV and AIDS states were 7.49 and 3.0 years 
respectively,2,23 the discount rate was 0.03, and no 
age-weighting was applied. The average age of 
infection was estimated using the Asian Epidemic 
Model. The mortality and AIDS disability that 
will take place after 2030 (and relate to HIV 
infections that occurred between 2010-2030) 
were included in the DALY estimates.
Estimate of Costs
Siregar et al estimated the costs of VCT in 
different delivery settings (public and private 
community health centers, hospitals, and prisons) 
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Sensitivity Analyses
We examined the robustness of baseline 
incremental cost-effectiveness ratios to parameter 
variations in a one-way sensitivity analysis. For 
the impact of VCT on the reduction in non-
condom use the uncertainty ranges as provided 
by the GOALS matrix were used. We varied 
coverage assumptions in the strategy of scaling 
up VCT and all costs components using a -/+ 25% 
approach. Other parameters, like AEM fitting 
variables, years of projection, clinic capacity, and 
most importantly epidemiological and behavioral 
variables were varied according to known 
uncertainty or a -/+25% approach. All uncertainty 
ranges are presented between brackets in an 
additional table in the online Appendix (www.
niche1.nl/publications).
RESULTS
Between 2010 and 2014, scaling up VCT will 
increase condom use for direct FSWs from 62% 
to 69%, for indirect FSWs from 60% to 67%, 
for MSM from 45% to 55%, for sexual contact 
between IDUs and FSWs from 54% to 62%, and 
for sexual contact between IDUs and spouses 
from 34% to 46%. Compared with the base 
case, scaling up VCT will decrease the overall 
HIV prevalence by 36%, from 0.44% to 0.28%, 
in West-Java in 2030. This reduction varies 
between most-at-risk populations: a decrease 
from 42.9% to 41.2% for IDUs, 34.0% to 21.7% 
for FSWs, and 15.7% to 9.8% for MSM. Up to 
2030, scaling up VCT will avert more than 94,000 
HIV infections (Figure 1), 41,000 AIDS cases 
and 26,000 deaths, and this corresponds to more 
than 2.5 million DALYs averted in West-Java.
Unit costs of VCT delivery settings range 
between US$14.91 at public community health 
centers and $68.74 at hospitals (Table 2). Over 
the period 2010-2030, scaling up VCT at the 
community level will cost US$60 million, 
compared to US$37 million if current practice 
is maintained. Scaling up VCT will cost US$1.3 
million in 2010, US$3.0 million in 2015, and 
US$3.8 million in 2030. The number of clinics 
integrated at public community health centers 
would need to increase from from 73 in 2010 to 
594 in 2030 in order to provide VCT services to 
more than 180,000 thousand people in West-Java 
in 2030.
Scaling up VCT (compared to the base case) 
costs US$248 per HIV infection averted and 
US$9.17 per DALY averted. As presented in 
Figure 2, ICER estimates were most sensitive to 
the impact of VCT on condom use, population 
size of clients of FSWs, HIV prevalence in the 
general population, population size of FSWs, and 
condom use between FSWs and clients. Costs per 
HIV infections averted range between US$104 
and US$1,758 and cost per DALY saved range 
between US$5 and US$65.
Figure 1. Impact of scaling up VCT on cumulative and current number of HIV infections in West-Java
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DISCUSSION
Our estimates show that implementation of 
the national strategy of scaling up community-
based VCT to 80% of the most-at-risk populations 
in West-Java could reduce the overall population 
prevalence by 36% in 2030 (from 0.44% to 
0.28%) and could avert a substantial amount of 
HIV-related morbidity and death. This strategy 
costs US$248 per HIV infection averted and 
US$9.17 per DALY saved. According to 
international thresholds put forward by WHO24, 
this intervention seems very cost-effective as 
it falls within the one-time per capita gross 
domestic product (i.e. US$2,963 in 2010).25 
Although our estimates are sensitive to parameter 
changes in the model, they do not exceed the 
threshold mentioned and therefore conclusions 
can be considered robust. Because the nature of 
the HIV epidemic is similar across Indonesia, 
with the exception of Papua province, study 
results can be generalized with caution.
Although scaling up community-based 
VCT is very effective and cost-effective it 
raises concerns: West-Java province will need 
between US$1.3 to US$3.8 million per year to 
spend on VCT; in 2010 the national HIV/AIDS 
expenditure for all programs in all 33 provinces 
together was US$50.8 million and 61% was 
Figure 2. Results of one-way sensitivity analysis of incremental costs per DALY saved
financed by international sources.3 However, the 
prioritization of VCT over other interventions 
could partially address this concern. Scaling up 
community-based VCT requires a substantial 
rise in the number of public community health 
centers that deliver VCT (from 73 in 2010 to 
almost 600 in 2030) and it is not certain whether 
this is feasible, although first steps in this process 
have already been taken successfully.7 Because 
of these budget and organizational constraints, 
cost-effectiveness alone should not guide priority 
setting in HIV/AIDS control in West-Java.26
Scaling up VCT is more cost-effective than 
MMT in West-Java. Wammes et al estimated that 
scaling up MMT to 20% in West-Java costs $269 
per DALY saved.13 Unfortunately, we cannot 
compare these results to the cost-effectiveness of 
other HIV/AIDS interventions in Indonesia due 
to a lack of data. Compared to other countries 
our estimates are in the same order of magnitude. 
In India and Kenya, VCT costs, respectively, 
US$665 and US$249 per HIV infection averted. 
In Peru, VCT costs US$116 per DALY saved.27-29
This study has a number of limitations. First, 
the AEM and RNM were not originally developed 
to conduct cost-effectiveness analysis and could 
not precisely reflect VCT in West-Java as some 
risk populations were not included. In addition, 
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the effectiveness data in the impact matrix (i.e. 
the impact of VCT on condom use) was not 
based on Indonesian evidence and the exclusion 
of some populations caused an underestimation 
of the effectiveness. However, our effectiveness 
assumption was validated by the literature and 
sensitivity analysis showed that conclusions are 
robust. Second, VCT was evaluated as a single 
intervention and the impact of increased need 
for antiretroviral treatment (ART) on budget and 
health effects was not included. We excluded 
ART because its implementation is a separate 
decision for the government; if we included it 
then the overall intervention would probably be 
even more cost- effective, as ART can reduce HIV 
transmission and therefore has large population 
effects. In addition, we analyzed costs from a 
governmental perspective and did not include 
patient costs, although a recent study in three 
settings in Indonesia showed a substantial 
financial burden of HIV/AIDS care for patients.30 
Third, economies of scale, cost inflation, indirect 
costs (productivity loss due to disability and early 
death), and interactions between interventions 
were not taken into account, because accurate 
data was not available. Fourth, scaling up VCT 
could face feasibility constraints, e.g. a lack 
of VCT counselors and political and cultural 
support, but this can be partially resolved by 
training community workers and by advocacy 
for prioritizing HIV/AIDS services. Fifth, we 
assume that high coverage of risk groups can 
be achieved although it is difficult to reach 
out to these populations. However, we see this 
assumption as a limitation of cost-effectiveness 
analysis in general. 
CONCLUSION
Scaling up community-based VCT seems 
an effective and cost-effective intervention. 
However, in order to prioritize VCT in HIV/AIDS 
control in West-Java, issues of budget availability 
and organizational capacity should be addressed. 
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